|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,010.00 GBX | +0.75% |
|
+2.45% | +0.85% |
| 14/07 | Hikma says launched Morphine Sulfate Injection in prefilled syringe in the US | RE |
| 02/07 | Hikma Receives FDA Approval for Tyzavan?? (Vancomycin Injection, USP) in the US | CI |
| Capitalization | 595.69Cr 511.1Cr 476.2Cr 443.07Cr 817.47Cr 51TCr 912.77Cr 5.75TCr 2.17TCr 24TCr 2.23TCr 2.19TCr 88TCr | P/E ratio 2025 * |
13.2x | P/E ratio 2026 * | 11.8x |
|---|---|---|---|---|---|
| Enterprise value | 689.45Cr 591.55Cr 551.16Cr 512.81Cr 946.14Cr 59TCr 1.06TCr 6.66TCr 2.51TCr 28TCr 2.59TCr 2.53TCr 1,02300Cr | EV / Sales 2025 * |
2.08x | EV / Sales 2026 * | 1.92x |
| Free-Float |
65.88% | Yield 2025 * |
3.08% | Yield 2026 * | 3.34% |
More valuation ratios
* Estimated data
More news
Last Transcript: Hikma Pharmaceuticals PLC
More recommendations
More press releases
More news
| 1 day | +0.75% | ||
| 1 week | +2.45% | ||
| Current month | +1.11% | ||
| 1 month | -2.71% | ||
| 3 months | +6.63% | ||
| 6 months | -3.64% | ||
| Current year | +0.85% |
| 1 week | 1,950 |  | 2,015.69 |
| 1 month | 1,950 | | 2,074 |
| Current year | 1,751 | | 2,360 |
| 1 year | 1,751 | | 2,360 |
| 3 years | 1,174.5 | | 2,360 |
| 5 years | 1,174.5 | | 2,768 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Riad Mishlawi
CEO | Chief Executive Officer | 61 | 01/09/2023 |
Khalid Nabilsi
DFI | Director of Finance/CFO | 53 | 01/01/2001 |
Hill Julie
CMP | Compliance Officer | - | 01/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 14/10/2005 | |
Said Darwazah
CHM | Chairman | 68 | 15/05/2014 |
Riad Mishlawi
BRD | Director/Board Member | 61 | 01/01/1990 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0.44% | 1,022 M€ | +19.39% | - | |
| 0.25% | 0 M€ | -.--% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.75% | +2.45% | +8.12% | +19.79% | 595.69Cr | ||
| +1.34% | -2.69% | -10.00% | +136.58% | 69TCr | ||
| +0.44% | +4.33% | +5.82% | -4.65% | 39TCr | ||
| -1.12% | -1.66% | +9.83% | +26.39% | 33TCr | ||
| -2.22% | -5.55% | -53.26% | -1.90% | 29TCr | ||
| +0.58% | +0.66% | -7.15% | -21.43% | 26TCr | ||
| -1.12% | -4.09% | -2.94% | +12.40% | 22TCr | ||
| -0.17% | -1.49% | -15.11% | -7.23% | 21TCr | ||
| -1.91% | -4.08% | -36.42% | -13.43% | 20TCr | ||
| -1.17% | -0.17% | -11.03% | +19.18% | 16TCr | ||
| Average | -0.46% | -1.33% | -11.21% | +16.57% | 27.71TCr | |
| Weighted average by Cap. | -0.22% | -1.66% | -11.34% | +35.08% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 331.39Cr 284.33Cr 264.92Cr 246.48Cr 454.77Cr 29TCr 507.78Cr 3.2TCr 1.21TCr 13TCr 1.24TCr 1.22TCr 49TCr | 347.75Cr 298.37Cr 278Cr 258.65Cr 477.22Cr 30TCr 532.85Cr 3.36TCr 1.27TCr 14TCr 1.3TCr 1.28TCr 52TCr |
| Net income | 46Cr 39Cr 37Cr 34Cr 63Cr 3.94TCr 70Cr 442.36Cr 166.99Cr 1.85TCr 171.81Cr 168.25Cr 6.8TCr | 52Cr 44Cr 41Cr 38Cr 71Cr 4.44TCr 79Cr 497.41Cr 187.77Cr 2.08TCr 193.19Cr 189.19Cr 7.64TCr |
| Net Debt | 94Cr 80Cr 75Cr 70Cr 128.67Cr 8.08TCr 143.67Cr 905.54Cr 341.83Cr 3.79TCr 351.71Cr 344.42Cr 14TCr | 71Cr 61Cr 57Cr 53Cr 98Cr 6.14TCr 109.33Cr 689.08Cr 260.12Cr 2.88TCr 267.63Cr 262.09Cr 11TCr |
More financial data
* Estimated data
Employees
9,500
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/25/18 | 2,010.00 p | +0.75% | 3,27,453 |
| 17/25/17 | 1,995.00 p | +1.06% | 4,69,816 |
| 16/25/16 | 1,974.00 p | -0.85% | 2,05,423 |
| 15/25/15 | 1,991.00 p | +0.81% | 3,56,534 |
| 14/25/14 | 1,975.00 p | +0.66% | 2,34,849 |
Delayed Quote London S.E., July 18, 2025 at 09:05 pm IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
27.02USD
Average target price
34.69USD
Spread / Average Target
+28.38%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition